News from medivir A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 10, 2021, 09:37 ET Medivir enters into licensing agreement with Ubiquigent for preclinical program USP7

Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent) for Medivir's...

Feb 08, 2021, 08:41 ET Notice of extraordinary general meeting of Medivir AB (publ)

The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary...

Feb 07, 2021, 15:24 ET Medivir Proposes Directed Issue of Approximately SEK 28 Million to the Company's Existing Specialist Investor LINC

The Board of Directors in Medivir AB (publ) ("Medivir" or the "Company") has decided to summon an extraordinary general meeting on 11 March 2021 to...

Jan 13, 2021, 06:17 ET Resolutions at the extraordinary general meeting in Medivir on 13 January 2021

Resolution regarding reduction of the share capital without cancellation of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on...

Jan 12, 2021, 02:46 ET Medivir presents MIV-818 data at ASCO Gastrointestinal Cancers Symposium

Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled "Phase I study of the novel pro-drug MIV-818 in patients with...

Jan 11, 2021, 22:22 ET Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant

Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences,...

Dec 11, 2020, 03:27 ET Notice of extraordinary general meeting of Medivir AB (publ)

The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary...

Dec 11, 2020, 03:05 ET Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant

Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") has renegotiated its agreement with TetraLogic...

Nov 10, 2020, 03:16 ET MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2020

Continued focus on MIV-818 July – September Significant events during the quarter In July, a research collaboration was initiated with the Drug...

Oct 05, 2020, 02:45 ET Medivir appoints Dr. Tom Morris as interim Chief Medical Officer

Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020. Dr....

Aug 20, 2020, 02:50 ET Medivir AB - Interim Report January - June 2020

April - June Significant events during the quarter Following the positive opinion given by the European Medicines Agency (EMA), the European...

Aug 18, 2020, 02:53 ET Yilmaz Mahshid takes office as CEO of Medivir on 14 September

Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who...

Jul 06, 2020, 02:41 ET Medivir and SciLifeLab Enter Collaboration on Potential SARS CoV-2 Inhibitors

Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery and Development Platform...

Jul 03, 2020, 01:39 ET The European Commission has Granted Orphan Medicinal Product Designation in the EU for MIV-818

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the European Medicines Agency...

May 26, 2020, 02:40 ET Medivir Appoints Yilmaz Mahshid as New CEO

Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz...

May 06, 2020, 02:47 ET FDA Grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to...

May 05, 2020, 10:42 ET Resolutions at the Annual General Meeting in Medivir on 5 May 2020

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual...

May 05, 2020, 02:51 ET Medivir AB - Interim Report January - March 2020

Positive results for MIV-818 and continued tempo in business development January - March Significant events during the quarter Data from the phase Ia ...

Apr 30, 2020, 02:59 ET Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818

Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan...

Apr 15, 2020, 10:18 ET Medivir Announces Departure of Chief Medical Officer

Medivir AB (Nasdaq Stockholm: MVIR) announces that Linda Basse, Chief Medical Officer at Medivir will leave the company on September 30, 2020. A...

Apr 06, 2020, 08:09 ET Medivir 2019 Annual Report Published

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the company's website: www.medivir.com. The...

Apr 06, 2020, 03:34 ET Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m. at Tändstickspalatset, Västra...

Mar 16, 2020, 03:50 ET Medivir and Tango Therapeutics Sign License Agreement for Preclinical Asset

Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one...

Mar 10, 2020, 04:18 ET First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818....

Mar 02, 2020, 02:40 ET Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818 in Patients With Advanced Liver Cancer

Medivir AB (Nasdaq Stockholm: MVIR) announces that new data from the completed phase Ia study with MIV-818 will be presented at the R&D day hosted by ...